netFormulary Coventry and Warwickshire Area Prescribing Committee NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of Epidermal Growth Factor Receptor TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer with activating eGFR mutation(s)
 
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
   
Alectinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of lung cancer
 
   
Cabozantinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal and thyroid cancer
 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
   
Dasatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of leukaemia
 
Link  NICE TA425: high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML)
Link  NICE TA426: for untreated chronic myeloid leukaemia
   
Everolimus
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal, breast and pancreatic cancer, renal angiomyelolipoma and subependymal giant cell astrocytoma
 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Gefitinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of non-small cell lung cancer
 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
   
Cytotoxic Drug Imatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of leukaemias, gastrointestinal stromal tumours, dermatofibrosarcoma protuberans, and myelodysplastic/myeloproliferative diseases
 
Link  NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
Link  NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Link  NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA70: Leukaemia (chronic myeloid) - imatinib
Link  NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
   
Lapatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of breast cancer
 
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
   
Nilotinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of chronic myeloid leukaemia
 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Nintedanib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of lung cancer
 
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
   
Osimertinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of lung cancer
 
   
Palbociclib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of breast cancer
 
   
Pazopanib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal cell carcinoma and soft tissue sarcoma
 
Link  NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
   
Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment colorectal cancer and gastrointestinal stromal tumours

 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
   
Sunitinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of gastro-intestinal and pancreatic tumours and renal cell carcinoma
 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA178: Renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Cytotoxic Drug Temsirolimus
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal cell carcinoma and mantle cell lymphoma
 
Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
   
Cytotoxic Drug Vandetanib (Caprelsa)
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of thyroid cancer
 
   
Vemurafenib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of melanoma
 
Link  NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Link  NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
   
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab to top
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Crizotinib

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended
Treatment of adults with previously treated anaplastic lymphoma kinase-positive advanced non-small cell lung cancer
Not recommended by NICE
Link  NICE TA296: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
 
Sorafenib  (Nexavar®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended
Advanced hepatocellular cancer
Link  NICE TA474: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Preferred

Clinicians are free to prescribe these drugs. They are regarded as cost effective choices which have evidence to support their use.  

Second Line

These drugs should only be prescribed in the scenarios described in the formulary after preferred drug(s) have been ruled out.  

Non Formulary

Non-formulary choice - the vast majority of a patient’s needs should be met by use of formulary preferred choices and second line options when appropriate. Therefore the Clinician should only use a non-formularly drug if this can be justified and it is recommended that all such instances are recorded in the patient record.  

Green SA

Specialist Advised – Specialists may simply advise a patient’s GP to initiate these drugs themselves after they have made an initial assessment. Note: SA drugs can be initiated by the specialist according to patient need and also depending on local commissioning arrangements which may mandate, through the contract between provider and commissioner, that all SA drugs are treated as SI.  

Green SI

Specialist Initiation - These drugs must be initiated, i.e. the first dose prescribed, by the specialist and then may be continued when appropriate by the patient’s GP following communication from the specialist.  

Amber SC

Shared Care - Responsibility for prescribing may be transferred from secondary to primary care with the agreement of an individual GP and when agreed shared care arrangements have been established. The specialist MUST stabilize the patient before asking for care to be transferred. Only specialists should initiate these drugs. Prescribing should be transferred to GPs according to an Shared Care Agreement [SCA]   

Red SO

Specialist Only - These drugs are deemed to be not appropriate for prescribing by GPs. Specialists should not ask GPs to prescribe these drugs.   

Black BL

Black Listed Medicines - These drugs are considered inappropriate for prescribing in Coventry & Warwickshire as they are either not cost-effective or of proven benefit or both.   

Not Recommended

Not Recommended - These are specialist drugs that are not recommended for use.  

Not Recommended / Black

These are specialist drugs that are not recommended for use and also, included on our local blacklist.  

netFormulary